Overweight or obesity is the leading cause of many diseases. To overcome obesity, doctors suggest eating healthy and doing exercise daily with a healthy lifestyle and by taking medication prof helpful to reduce the weight. Glucagon is the main component that is helpful to lose weight. Several medicines have Glucagon peptide as their formula, which helps reduce weight with a healthy lifestyle. These medications and changing patterns of lifestyle prove effective for weight loss.
Our brain sends signals to the GLP-1, potent hormones made by the body to reduce your appetite, improve your metabolic function, to increase satiety. People who are overweight show a decrease in GLP-1 signalling and research shows. The doctor's prescription drugs work on the same receptors for your natural GLP-1 hormones.
The approved GLP-1 is a naturally occurring hormone helping you to eat less and feel fuller and more satisfied. The GLP-1 medications available today can help you lose weight by safely lowering your set point.
Different studies on Ozempic and Semaglutide show that it is a game-changer and effective in weight loss. Semaglutideand Wegovy just got approved European Medicine Agency for weight loss and treating obesity. Ozempic is currently not licenced, but Wegovy just got its licence in the EU.
Semaglutide Treatment Effect on Weight Loss(Different research studies, information about Semaglutide)
The first STEP1 study, authored by Professor John Wilding, Professor Rachel Batterham, and other co-authors, was just published in The New England Journal of Medicine under the title "Once-Weekly Semaglutide in Adults With Overweight or Obesity."
Over the course of a 68-week study, those who received Semaglutide injection once a week lost about 15% of their body weight compared to those who received a placebo (2.4% weight loss).
The Ozempic®, which is Semgalutide licensed for type 2 diabetes, is administered in a considerably lower dose (maximum one milligram) than the weight drug, Wegovy®, used in this study (2.4milligrams).
The study reveals that when people took Semaglutide and received a healthy lifestyle change, they were able to lose weight. Because of adverse effects, more individuals on this treatment stopped taking it. The most frequent side effects associated with Semaglutide: are nausea and diarrhoea. The side effect usually occurs after the first dose and can be easily managed with a small dose of Esomeprazole.
The results show that the Semaglutide-taking group lost weight about 15% other than the placebo group, which lost only 2.4%
It is seen from the research studies that Semaglutide injection proves helpful in reducing weight. Overweight people who can use the medicine and adopt a healthy lifestyle will lose weight.
As the number of adults with type 2 diabetes grows worldwide, researchers are conducting more research to assist people in managing their diabetes effectively and avoid problems. Over the last ten years, new drugs have been produced. Approximately 90% of individuals with Type 2 diabetes are either overweight or obese. We all know that lowering weight can assist blood sugar management and sometimes eliminate type 2 diabetes. Medications for diabetes are designed not just to reduce blood glucose levels but also to target weight gain.
We'll look at a new diabetes cure that is still in the early stages of development, known as Semaglutide. This drug is a GLP-1(Glucagon-Like Peptide-1) metabolite. The commercial name for this medication is Ozempic® and Wegovy®.
GLP-1 is a natural hormone that has several effects on glucose and appetite control. Changes in the pancreas and brain regulate blood glucose and hunger. The hormone Glucagon, Peptide, or GLP-1 plays an important role.
GLP-1 works by stimulating insulin production, which only works when blood glucose is high and does not stimulate insulin production if blood glucose levels are low.
It also inhibits glucagon secretion in response to blood glucose levels higher than normal. Glucagon is a hormone that raises blood sugar levels. When blood glucose levels are low, the pancreas normally produces glucagon.
Glucagon converts the liver's glycogen to glucose. After eating, gastric emptying is momentarily delayed, lowering blood sugar levels. Semaglutide lowers insulin production when blood glucose levels are low.
It is also claimed to help you lose weight and fat by reducing your food consumption and cravings. Ozempic® also decreases the preference for high-fat foods.
Ozempic® (or Semaglutide) is a GLP-1 analogue and is given as an injection once a week.
Ozempic® was superior at lowering HbA1c (Glycosylated haemoglobin, a measure of blood glucose control) from baseline compared to dulaglutide, exenatide OW, sitagliptin, and insulin glargine, according to research.
For all comparisons, semaglutide (Ozempic®) 1 mg was superior and resulted in greater weight reduction from baseline than dulaglutide (another GLP-1 analogue), exenatide (weekly), sitagliptin, and insulin glargine.
Ozempic® treatment reduced the chance of dying from cardiovascular causes by 26%, non-fatal heart attack or non-fatal stroke.
Ozempic®, like other GLP-1 analogues, has been found to lower blood pressure and improve plasma lipids.
which means it is a glucagon-like peptide taken in the form of injection, only a small amount of one milligram, and in a week once.
Different research studies give information that Semaglutide or Ozempic is considered a medicine that can reduce the Hemoglobin Glycosylated and considered superior from all the available drugs in the market. Semaglutide is superior in weight loss to Sitagliptin and the drugs mentioned above in every comparison. It is superior to Insulin Glargine, Dulaglutide, Sitagliptin, and Exenatide OW. 1 milligram of Ozempic is enough for a weight loss of about 15 kg. In contrast, Dulaglutide is taken at 3.5 milligrams, and it loses only 6.5 kg of body weight.
Ozempic also puts forward many benefits in the reduction of many other diseases. When a type 2 diabetic patient is treated with Ozempic (Semaglutide) to treat obesity results show that Ozempic helps to reduce the risk of cardiovascular diseases by 26%. It helps to minimise fatal heart attacks.
At the same time, the glucagon peptide in the Semaglutiide helps reduce blood pressure and maintain the liquid plasma level in the blood.
The use of Semaglutide in persons with diabetes mellitus type 1 or diabetic ketoacidosis is not recommended. Semaglutide is not a substitute for insulin and should be used alongside it.
Patients with heart failure should not take Semaglutide. The New York Heart Association has classified it as a class IV drug.
The use of GLP-1 receptor agonists has been linked to acute pancreatitis or inflammation of the pancreas. Abdominal discomfort, loss of appetite, nausea and vomiting are symptoms of acute pancreatitis. If pancreatitis is suspected, go to the closest A&E immediately.
If you have been diagnosed with pancreatitis, stop taking Semaglutide right away; if the diagnosis is confirmed, do not resume Semaglutide.
Patients treated with Semaglutide or any GLP-1 analogue in combination with a sulfonylurea or insulin may have an elevated risk of hypoglycemia (low blood glucose levels of less than 4mmol/l or 72mg/dl). When starting treatment with GLP-1 analogue, the risk may be lowered by lowering the dose of sulfonylureas, such as gliclazide or insulin.
When receiving Ozempic®, women of childbearing potential should use contraception. As a result, Ozempic® should not be used during pregnancy because there is no information about its safety.